comparison of two doses of buprenorphine as spinal Adjuvant to 0.5% Bupivacaine for adult patients undergoing lower limb orthopedic surgeries

A Prospective Randomized Double Blind Controlled study of comparison of two doses of buprenorphine as spinal Adjuvant to 0.5% Bupivacaine for adult patients undergoing lower limb orthopedic surgeries - nil

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/065175

Enrollment

Registered

2024-04-03

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M849- Disorder of continuity of bone, unspecified

Interventions

Intervention1: 60 micrograms of buprenorphine: aim is to compare 60 micrograms of buprenorphine with 45 micrograms of buprenorphine when given as spinal adjuvant in subarachnoid space. effect of both

Eligibility

Inclusion criteria

Inclusion criteria: . American Society of Anesthesiologists Grade I and II patients. . Adult patients aged more than 18 years of either gender. . Patients undergoing lower limb orthopedic surgeries. . Height is more than 4 feet.

Exclusion criteria

Exclusion criteria: . American Society of Anesthesiologist Grade III and IV patients. . Patients with known contraindications for spinal anesthesia: bleeding disorders, local Infection. . Patients with hemodynamic instability. . Patients with allergy to or history of hypersensitivity to local anesthetics. . Emergency surgeries. . Patients with known allergy to opioids. .Patients refusal.

Design outcomes

Primary

Measure	Time frame
inreased duration of sensory & motor blockadeTimepoint: 15min 30min 45min	—

Secondary

Measure	Time frame
onset & level of sensory and motor blockade achievedTimepoint: 15min 30min 45min	—

Countries

India

Contacts

Public Contactshivaji ramesh gavali

Mahatma Gandhi institute of medical sciences,Sevagram

suchetatidke@mgims.ac.in9850510019

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026